|
Gene: SLC26A4 |
Gene summary for SLC26A4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC26A4 | Gene ID | 5172 |
Gene name | solute carrier family 26 member 4 | |
Gene Alias | DFNB4 | |
Cytomap | 7q22.3 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | O43511 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5172 | SLC26A4 | HCC1 | Human | Liver | HCC | 8.93e-06 | 8.77e-01 | 0.5336 |
5172 | SLC26A4 | HCC2 | Human | Liver | HCC | 4.73e-18 | 1.38e+00 | 0.5341 |
5172 | SLC26A4 | HCC5 | Human | Liver | HCC | 2.78e-22 | 1.54e+00 | 0.4932 |
5172 | SLC26A4 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 1.18e-35 | -1.08e+00 | 0.02 |
5172 | SLC26A4 | Adj_PTCwithHT_8 | Human | Thyroid | HT | 3.11e-05 | -5.79e-01 | 0.0267 |
5172 | SLC26A4 | PTCwithHT_1 | Human | Thyroid | HT | 5.19e-09 | -1.04e+00 | 0.0238 |
5172 | SLC26A4 | PTCwithHT_6 | Human | Thyroid | HT | 3.80e-36 | -1.08e+00 | 0.02 |
5172 | SLC26A4 | PTCwithHT_8 | Human | Thyroid | HT | 4.19e-39 | -1.07e+00 | 0.0351 |
5172 | SLC26A4 | PTCwithoutHT_2 | Human | Thyroid | PTC | 8.07e-34 | -1.02e+00 | 0.0419 |
5172 | SLC26A4 | PTCwithoutHT_7 | Human | Thyroid | PTC | 1.71e-11 | -1.10e+00 | 0.0381 |
5172 | SLC26A4 | male-WTA | Human | Thyroid | PTC | 1.05e-30 | -4.75e-01 | 0.1037 |
5172 | SLC26A4 | PTC01 | Human | Thyroid | PTC | 1.89e-32 | -8.81e-01 | 0.1899 |
5172 | SLC26A4 | PTC03 | Human | Thyroid | PTC | 2.16e-04 | -6.93e-01 | 0.1784 |
5172 | SLC26A4 | PTC04 | Human | Thyroid | PTC | 2.12e-13 | -6.56e-01 | 0.1927 |
5172 | SLC26A4 | PTC05 | Human | Thyroid | PTC | 3.16e-09 | -8.87e-01 | 0.2065 |
5172 | SLC26A4 | PTC06 | Human | Thyroid | PTC | 8.47e-14 | -7.85e-01 | 0.2057 |
5172 | SLC26A4 | PTC07 | Human | Thyroid | PTC | 1.03e-14 | -7.23e-01 | 0.2044 |
5172 | SLC26A4 | ATC08 | Human | Thyroid | ATC | 5.64e-08 | -1.01e+00 | 0.0541 |
5172 | SLC26A4 | ATC09 | Human | Thyroid | ATC | 4.57e-12 | -1.10e+00 | 0.2871 |
5172 | SLC26A4 | ATC11 | Human | Thyroid | ATC | 3.09e-02 | -1.10e+00 | 0.3386 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC26A4 | SNV | Missense_Mutation | c.311N>T | p.Ala104Val | p.A104V | O43511 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SLC26A4 | SNV | Missense_Mutation | c.1126N>A | p.Asp376Asn | p.D376N | O43511 | protein_coding | tolerated(0.13) | benign(0.246) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SLC26A4 | SNV | Missense_Mutation | novel | c.1486C>A | p.Leu496Ile | p.L496I | O43511 | protein_coding | tolerated(0.21) | benign(0.2) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC26A4 | SNV | Missense_Mutation | rs150597240 | c.2291N>T | p.Thr764Met | p.T764M | O43511 | protein_coding | tolerated_low_confidence(0.27) | benign(0.074) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC26A4 | SNV | Missense_Mutation | novel | c.2263N>G | p.Thr755Ala | p.T755A | O43511 | protein_coding | deleterious(0.02) | benign(0) | TCGA-BH-A1EY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SLC26A4 | SNV | Missense_Mutation | rs879139093 | c.229A>C | p.Lys77Gln | p.K77Q | O43511 | protein_coding | tolerated(0.5) | benign(0.027) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
SLC26A4 | SNV | Missense_Mutation | rs879139093 | c.229N>C | p.Lys77Gln | p.K77Q | O43511 | protein_coding | tolerated(0.5) | benign(0.027) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
SLC26A4 | SNV | Missense_Mutation | rs879139093 | c.229A>C | p.Lys77Gln | p.K77Q | O43511 | protein_coding | tolerated(0.5) | benign(0.027) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
SLC26A4 | SNV | Missense_Mutation | c.1819N>T | p.Asp607Tyr | p.D607Y | O43511 | protein_coding | deleterious(0.04) | benign(0.285) | TCGA-E9-A1NF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
SLC26A4 | SNV | Missense_Mutation | rs879139093 | c.229N>C | p.Lys77Gln | p.K77Q | O43511 | protein_coding | tolerated(0.5) | benign(0.027) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |